Stock Analysis

Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt Responsibly

KOSDAQ:A200670
Source: Shutterstock

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. Importantly, Humedix Co., Ltd. (KOSDAQ:200670) does carry debt. But should shareholders be worried about its use of debt?

When Is Debt A Problem?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

See our latest analysis for Humedix

What Is Humedix's Debt?

As you can see below, at the end of September 2020, Humedix had ₩24.2b of debt, up from ₩1.18b a year ago. Click the image for more detail. But on the other hand it also has ₩36.2b in cash, leading to a ₩12.0b net cash position.

debt-equity-history-analysis
KOSDAQ:A200670 Debt to Equity History December 2nd 2020

How Strong Is Humedix's Balance Sheet?

The latest balance sheet data shows that Humedix had liabilities of ₩37.8b due within a year, and liabilities of ₩3.62b falling due after that. On the other hand, it had cash of ₩36.2b and ₩24.9b worth of receivables due within a year. So it can boast ₩19.7b more liquid assets than total liabilities.

This surplus suggests that Humedix has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Simply put, the fact that Humedix has more cash than debt is arguably a good indication that it can manage its debt safely.

The good news is that Humedix has increased its EBIT by 6.7% over twelve months, which should ease any concerns about debt repayment. There's no doubt that we learn most about debt from the balance sheet. But it is Humedix's earnings that will influence how the balance sheet holds up in the future. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. While Humedix has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. Looking at the most recent three years, Humedix recorded free cash flow of 21% of its EBIT, which is weaker than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.

Summing up

While it is always sensible to investigate a company's debt, in this case Humedix has ₩12.0b in net cash and a decent-looking balance sheet. And it also grew its EBIT by 6.7% over the last year. So we don't have any problem with Humedix's use of debt. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. To that end, you should learn about the 2 warning signs we've spotted with Humedix (including 1 which is shouldn't be ignored) .

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

When trading Humedix or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if Humedix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.